Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ANIK's Cash-to-Debt is ranked higher than
97% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ANIK: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ANIK' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.5  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
ANIK's Equity-to-Asset is ranked higher than
91% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ANIK: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
ANIK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49  Med: 0.77 Max: 0.94
Current: 0.92
0.49
0.94
Interest Coverage No Debt
ANIK's Interest Coverage is ranked higher than
97% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANIK' s Interest Coverage Range Over the Past 10 Years
Min: 38.66  Med: 256.75 Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 26.41
Beneish M-Score: -2.44
WACC vs ROIC
8.80%
35.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 46.84
ANIK's Operating Margin % is ranked higher than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ANIK: 46.84 )
Ranked among companies with meaningful Operating Margin % only.
ANIK' s Operating Margin % Range Over the Past 10 Years
Min: 11.81  Med: 24.6 Max: 58.19
Current: 46.84
11.81
58.19
Net Margin % 30.44
ANIK's Net Margin % is ranked higher than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ANIK: 30.44 )
Ranked among companies with meaningful Net Margin % only.
ANIK' s Net Margin % Range Over the Past 10 Years
Min: 7.77  Med: 18.03 Max: 36.29
Current: 30.44
7.77
36.29
ROE % 15.19
ANIK's ROE % is ranked higher than
90% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ANIK: 15.19 )
Ranked among companies with meaningful ROE % only.
ANIK' s ROE % Range Over the Past 10 Years
Min: 5.16  Med: 11.78 Max: 24.43
Current: 15.19
5.16
24.43
ROA % 14.05
ANIK's ROA % is ranked higher than
94% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ANIK: 14.05 )
Ranked among companies with meaningful ROA % only.
ANIK' s ROA % Range Over the Past 10 Years
Min: 3.27  Med: 8.37 Max: 21.97
Current: 14.05
3.27
21.97
ROC (Joel Greenblatt) % 61.55
ANIK's ROC (Joel Greenblatt) % is ranked higher than
92% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ANIK: 61.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANIK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.35  Med: 40.48 Max: 110.18
Current: 61.55
13.35
110.18
3-Year Revenue Growth Rate 10.50
ANIK's 3-Year Revenue Growth Rate is ranked higher than
61% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ANIK: 10.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ANIK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.4  Med: 7.5 Max: 26.7
Current: 10.5
-4.4
26.7
3-Year EBITDA Growth Rate 12.60
ANIK's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ANIK: 12.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANIK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.4  Med: 19.35 Max: 91.7
Current: 12.6
-64.4
91.7
3-Year EPS without NRI Growth Rate 15.60
ANIK's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ANIK: 15.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ANIK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64.3  Med: 20.15 Max: 72.4
Current: 15.6
-64.3
72.4
GuruFocus has detected 3 Warning Signs with Anika Therapeutics Inc $ANIK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANIK's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ANIK Guru Trades in Q3 2016

Paul Tudor Jones 12,831 sh (New)
Ken Fisher 93,715 sh (+62.36%)
Jim Simons 207,700 sh (-23.39%)
Joel Greenblatt 79,286 sh (-60.02%)
» More
Q4 2016

ANIK Guru Trades in Q4 2016

Paul Tudor Jones 17,069 sh (+33.03%)
Jim Simons 166,800 sh (-19.69%)
Ken Fisher 59,234 sh (-36.79%)
Joel Greenblatt 42,279 sh (-46.68%)
» More
Q1 2017

ANIK Guru Trades in Q1 2017

Columbia Wanger 170,229 sh (New)
Jim Simons 253,100 sh (+51.74%)
Paul Tudor Jones 25,275 sh (+48.08%)
Ken Fisher 70,153 sh (+18.43%)
Joel Greenblatt 22,664 sh (-46.39%)
» More
Q2 2017

ANIK Guru Trades in Q2 2017

Columbia Wanger 275,624 sh (+61.91%)
Joel Greenblatt 33,826 sh (+49.25%)
Ken Fisher 80,904 sh (+15.33%)
Jim Simons 144,900 sh (-42.75%)
Paul Tudor Jones 13,919 sh (-44.93%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ANIK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 15.33%$43.04 - $49.68 $ 56.1122%80,904
Joel Greenblatt 2017-06-30 Add 49.25%0.01%$43.04 - $49.68 $ 56.1122%33,826
Ken Fisher 2017-03-31 Add 18.43%$41.72 - $52.23 $ 56.1118%70,153
Joel Greenblatt 2017-03-31 Reduce -46.39%0.01%$41.72 - $52.23 $ 56.1118%22,664
Ken Fisher 2016-12-31 Reduce -36.79%$41.44 - $50.02 $ 56.1121%59,234
Joel Greenblatt 2016-12-31 Reduce -46.68%0.02%$41.44 - $50.02 $ 56.1121%42,279
Ken Fisher 2016-09-30 Add 62.36%$45.82 - $54.26 $ 56.1114%93,715
Joel Greenblatt 2016-09-30 Reduce -60.02%0.08%$45.82 - $54.26 $ 56.1114%79,286
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 3841
Compare:NAS:NTLA, NAS:AKBA, NAS:VNDA, NAS:TGTX, NAS:RETA, NAS:PTCT, NAS:ADRO, NAS:KERX, NAS:ITCI, NAS:SPPI, NAS:ENTA, NAS:BYSI, NAS:EDIT, NAS:RGNX, NAS:IMGN, NAS:CYTK, NAS:RVNC, NAS:ZIOP, NAS:GTHX, NAS:AMRI » details
Traded in other countries:AKP.Germany,
Headquarter Location:USA
Anika Therapeutics Inc develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.

Anika Therapeutics Inc was incorporated in 1992 as a Massachusetts company. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid, or HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its biophysical and biochemical properties, HA performs physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. The Company through its subsidiary has over 20 products currently commercialized, mainly in Europe. These products are made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. Its Orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its Dermal products consist of wound care products, based on the HYAFF technology, and aesthetic dermal fillers. The HYAFF technology offers products for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents,therapies to aid healing and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products include AMVISC and AMVISC Plus product line, STAARVISC-IITM, Optivisc, AnikaVisc and AnikaVisc Plus which are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. Hyalobarrier is a clinically post-operative adhesion barrier for use in the abdomino-pelvic area. The product is currently commercialized in Europe, the Middle East and certain Asian countries through a distribution network, but is not approved in the U.S. INCERT, approved for sale in Europe, Turkey, and Malaysia. It is chemically modified, cross-linked HA product for the prevention of spinal post-surgical adhesions. The Company along with its subsidiary offers products used in connection with the treatment of ENT disorders. The products are Merogel, a woven fleece nasal

Top Ranked Articles about Anika Therapeutics Inc

6 Stocks Young Warren Buffett Would Buy in 2017 Technology and health care companies offer strong value potential
Six technology and health care companies made both the Undervalued Predictable Screener and the Buffett-Munger Screener as of May 4: Anika Therapeutics Inc. (NASDAQ:ANIK), NIC Inc. (NASDAQ:EGOV), Express Scripts Holding Co. (NASDAQ:ESRX), F5 Networks Inc. (NASDAQ:FFIV), CGI Group Inc. (NYSE:GIB) and Novo Nordisk A/S (NYSE:NVO). As these companies offer good growth and value potential, gurus are buying shares in these companies. Read more...
6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017 A deeper look at the value screeners and FZM scores
As discussed in previous articles, the GuruFocus value screeners can identify strong value opportunities for short-term and long-term investing. The following six companies made multiple value screeners as of Mar. 29: Wipro Ltd. (NYSE:WIT), The Cheesecake Factory Inc. (NASDAQ:CAKE), Casey’s General Stores Inc. (NASDAQ:CASY), Anika Therapeutics Inc. (NASDAQ:ANIK), F5 Networks Inc. (NASDAQ:FFIV) and Copart Inc. (NASDAQ:CPRT). These six companies offer strong value potential for second-quarter 2017. Read more...
Steven Romick Spots Next Area of Investment Interest: Health Care Romick has third of portfolio in cash, awaiting opportunities
At the $33.1 billion FPA Crescent Fund, widely followed stock manager Steven Romick (Trades, Portfolio) puts avoiding risk first, but he also embraces volatile markets to make steely buys of plummeting equities. Read more...

Ratios

vs
industry
vs
history
PE Ratio 24.83
ANIK's PE Ratio is ranked higher than
62% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ANIK: 24.83 )
Ranked among companies with meaningful PE Ratio only.
ANIK' s PE Ratio Range Over the Past 10 Years
Min: 8.57  Med: 20.1 Max: 46.32
Current: 24.83
8.57
46.32
Forward PE Ratio 32.68
ANIK's Forward PE Ratio is ranked lower than
65% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. ANIK: 32.68 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.83
ANIK's PE Ratio without NRI is ranked higher than
63% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. ANIK: 24.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
ANIK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.57  Med: 20.1 Max: 46.32
Current: 24.83
8.57
46.32
Price-to-Owner-Earnings 28.86
ANIK's Price-to-Owner-Earnings is ranked higher than
53% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. ANIK: 28.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ANIK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.32  Med: 27.62 Max: 470.43
Current: 28.86
12.32
470.43
PB Ratio 3.35
ANIK's PB Ratio is ranked higher than
59% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ANIK: 3.35 )
Ranked among companies with meaningful PB Ratio only.
ANIK' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 2.43 Max: 4.63
Current: 3.35
0.58
4.63
PS Ratio 7.58
ANIK's PS Ratio is ranked higher than
62% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ANIK: 7.58 )
Ranked among companies with meaningful PS Ratio only.
ANIK' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 4.4 Max: 9.17
Current: 7.58
1
9.17
Price-to-Free-Cash-Flow 27.76
ANIK's Price-to-Free-Cash-Flow is ranked lower than
61% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. ANIK: 27.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ANIK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.43  Med: 20.46 Max: 1204.17
Current: 27.76
10.43
1204.17
Price-to-Operating-Cash-Flow 21.93
ANIK's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. ANIK: 21.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ANIK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.92  Med: 19.01 Max: 954.44
Current: 21.93
8.92
954.44
EV-to-EBIT 13.03
ANIK's EV-to-EBIT is ranked higher than
71% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ANIK: 13.03 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIK' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.8  Med: 10.75 Max: 37.9
Current: 13.03
1.8
37.9
EV-to-EBITDA 12.14
ANIK's EV-to-EBITDA is ranked higher than
69% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ANIK: 12.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANIK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.4  Med: 9.3 Max: 34
Current: 12.14
1.4
34
EV-to-Revenue 6.11
ANIK's EV-to-Revenue is ranked higher than
69% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ANIK: 6.11 )
Ranked among companies with meaningful EV-to-Revenue only.
ANIK' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 3.2 Max: 7.5
Current: 6.11
0.2
7.5
PEG Ratio 1.00
ANIK's PEG Ratio is ranked higher than
71% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. ANIK: 1.00 )
Ranked among companies with meaningful PEG Ratio only.
ANIK' s PEG Ratio Range Over the Past 10 Years
Min: 0.29  Med: 0.65 Max: 32.24
Current: 1
0.29
32.24
Shiller PE Ratio 45.27
ANIK's Shiller PE Ratio is ranked higher than
54% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. ANIK: 45.27 )
Ranked among companies with meaningful Shiller PE Ratio only.
ANIK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.29  Med: 39.78 Max: 120.42
Current: 45.27
14.29
120.42
Current Ratio 14.35
ANIK's Current Ratio is ranked higher than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ANIK: 14.35 )
Ranked among companies with meaningful Current Ratio only.
ANIK' s Current Ratio Range Over the Past 10 Years
Min: 2.84  Med: 7.09 Max: 23.7
Current: 14.35
2.84
23.7
Quick Ratio 13.04
ANIK's Quick Ratio is ranked higher than
90% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ANIK: 13.04 )
Ranked among companies with meaningful Quick Ratio only.
ANIK' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 5.55 Max: 21.67
Current: 13.04
1.21
21.67
Days Inventory 248.94
ANIK's Days Inventory is ranked lower than
79% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. ANIK: 248.94 )
Ranked among companies with meaningful Days Inventory only.
ANIK' s Days Inventory Range Over the Past 10 Years
Min: 98.12  Med: 152.44 Max: 248.94
Current: 248.94
98.12
248.94
Days Sales Outstanding 99.80
ANIK's Days Sales Outstanding is ranked lower than
55% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ANIK: 99.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.27  Med: 94.23 Max: 109.78
Current: 99.8
55.27
109.78
Days Payable 80.00
ANIK's Days Payable is ranked higher than
67% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ANIK: 80.00 )
Ranked among companies with meaningful Days Payable only.
ANIK' s Days Payable Range Over the Past 10 Years
Min: 20.94  Med: 62.17 Max: 169.68
Current: 80
20.94
169.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
ANIK's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ANIK: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANIK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -44.7  Med: -2.7 Max: -0.2
Current: -0.8
-44.7
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.74
ANIK's Price-to-Net-Cash is ranked higher than
59% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ANIK: 6.74 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ANIK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.48  Med: 7.15 Max: 79.94
Current: 6.74
0.48
79.94
Price-to-Net-Current-Asset-Value 4.78
ANIK's Price-to-Net-Current-Asset-Value is ranked higher than
66% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ANIK: 4.78 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ANIK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.34  Med: 4.3 Max: 40.16
Current: 4.78
0.34
40.16
Price-to-Tangible-Book 3.65
ANIK's Price-to-Tangible-Book is ranked higher than
64% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ANIK: 3.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ANIK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.29  Med: 2.65 Max: 13.3
Current: 3.65
0.29
13.3
Price-to-Intrinsic-Value-Projected-FCF 1.58
ANIK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. ANIK: 1.58 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ANIK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 1.82 Max: 20.72
Current: 1.58
0.54
20.72
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.87
ANIK's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
81% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. ANIK: 0.87 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ANIK' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.7  Med: 0.8 Max: 1.59
Current: 0.87
0.7
1.59
Price-to-Median-PS-Value 1.72
ANIK's Price-to-Median-PS-Value is ranked lower than
80% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ANIK: 1.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANIK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.9 Max: 2.13
Current: 1.72
0.11
2.13
Price-to-Peter-Lynch-Fair-Value 1.34
ANIK's Price-to-Peter-Lynch-Fair-Value is ranked higher than
74% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. ANIK: 1.34 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ANIK' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.85 Max: 5.53
Current: 1.34
0.37
5.53
Price-to-Graham-Number 2.01
ANIK's Price-to-Graham-Number is ranked higher than
67% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. ANIK: 2.01 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ANIK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.49  Med: 1.7 Max: 7.69
Current: 2.01
0.49
7.69
Earnings Yield (Greenblatt) % 7.69
ANIK's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ANIK: 7.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANIK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 9.3 Max: 56.4
Current: 7.69
2.6
56.4
Forward Rate of Return (Yacktman) % 21.48
ANIK's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. ANIK: 21.48 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ANIK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.3  Med: 21.7 Max: 54.5
Current: 21.48
-10.3
54.5

More Statistics

Revenue (TTM) (Mil) $111.36
EPS (TTM) $ 2.26
Beta1.10
Short Percentage of Float12.10%
52-Week Range $41.38 - 56.85
Shares Outstanding (Mil)14.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 117 120 127
EPS ($) 1.99 1.87 1.88
EPS without NRI ($) 1.99 1.87 1.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)
» More Articles for NAS:ANIK

Headlines

Articles On GuruFocus.com
7 Cheap Stocks With Growing Book Value Jun 30 2017 
6 Stocks Young Warren Buffett Would Buy in 2017 May 05 2017 
6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017 Mar 30 2017 
Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017 
Top Medical Companies Reach High Financial Strength Jul 19 2016 
Four Stocks With Growing EPS Near Their 52-Week Lows - Part II Jul 02 2015 
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Nov 03 2009 

More From Other Websites
Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs Aug 28 2017
ETFs with exposure to Anika Therapeutics, Inc. : August 15, 2017 Aug 15 2017
Anika (ANIK) Grows in Orthopedic Medicines on Positive Data Aug 15 2017
Edited Transcript of ANIK earnings conference call or presentation 27-Jul-17 1:00pm GMT Aug 13 2017
Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in... Aug 07 2017
Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Aug 01 2017
Anika Announces Appointment of Joseph Darling as President Jul 27 2017
Investor Network: Anika Therapeutics, Inc. to Host Earnings Call Jul 27 2017
Anika posts 2Q profit Jul 26 2017
Anika Reports Strong Second Quarter 2017 Financial Results Jul 26 2017
Anika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : July 26,... Jul 26 2017
Anika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated... Jul 24 2017
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics,... Jul 18 2017
Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC Jul 17 2017
Anika pays former medical chief $350K to thwart possible lawsuit Jul 17 2017
4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings Jul 17 2017
Anika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26 Jul 12 2017
Anika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : July 12, 2017 Jul 12 2017
ETFs with exposure to Anika Therapeutics, Inc. : July 11, 2017 Jul 11 2017
New Strong Sell Stocks for July 11th Jul 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}